Literature DB >> 19749008

Increased relative mortality in women with severe oxygen-dependent COPD.

Magnus Ekström1, Karl A Franklin, Kerstin E Ström.   

Abstract

BACKGROUND: Although the incidence of COPD is rapidly increasing in women, knowledge is lacking concerning differences in relative mortality and causes of death in women compared with men. We aimed to analyze differences in relative mortality and cause-specific mortality between men and women on long-term oxygen therapy (LTOT) for COPD.
METHODS: Patients starting LTOT for COPD in Sweden between January 1, 1987, and December 31, 2004, were prospectively followed until termination of LTOT or through December 31, 2004. Causes of death according to the Swedish National Causes of Death Register were compared between the study group and the general Swedish population matched for age and sex, with the relative mortality expressed as standardized mortality rates (SMRs).
RESULTS: A total of 7,646 patients, 4,033 women and 3,613 men, were followed for a median of 1.7 years (range 0-18.0). No patient was lost to follow-up. A total of 5,448 patients, 2,745 women and 2,703 men, died. Women had a higher SMR than men: overall mortality, SMR 12.0 (95%, 11.6-12.5) vs 7.4 (95% CI, 7.1-7.6); for respiratory disease, SMR 127.9 (95% CI, 122.4-133.6) vs 66.0 (95% CI, 63.1-69.0); cancer, SMR 3.5 (95% CI, 3.0-3.9) vs 2.2 (95% CI, 1.9-2.5); and cardiovascular disease, SMR 3.7 (95% CI, 3.3-4.1) vs 2.5 (95% CI, 2.3-2.7), respectively.
CONCLUSIONS: In severe COPD treated with long-term oxygen, women have higher relative mortality than men both overall and for respiratory disease, as well as for cardiovascular disease and cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19749008     DOI: 10.1378/chest.09-0636

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01

2.  Clinical COPD Questionnaire score (CCQ) and mortality.

Authors:  Josefin Sundh; Christer Janson; Karin Lisspers; Scott Montgomery; Björn Ställberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-12-20

3.  Appraising relative and excess mortality in population-based studies of chronic diseases such as end-stage renal disease.

Authors:  Caroline Elie; Y De Rycke; Jp Jais; P Landais
Journal:  Clin Epidemiol       Date:  2011-05-10       Impact factor: 4.790

4.  The risk of burn injury during long-term oxygen therapy: a 17-year longitudinal national study in Sweden.

Authors:  Hanan A Tanash; Fredrik Huss; Magnus Ekström
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-11-13

5.  Risk of cancer after lung transplantation for COPD.

Authors:  Magnus Ekström; Gerdt C Riise; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-03

6.  Validation of the Swedevox registry of continuous positive airway pressure, long-term mechanical ventilator and long-term oxygen therapy.

Authors:  Magnus Ekström; Dirk Albrecht; Susanne Andersson; Ludger Grote; Birgitta Kärrsten Rundström; Andreas Palm; Jenny Theorell-Haglöw; Josefin Wahlberg; Bengt Midgren
Journal:  ERJ Open Res       Date:  2021-01-18

7.  Adverse Effects, Smoking, Alcohol Consumption, and Quality of Life during Long-Term Oxygen Therapy: A Nationwide Study.

Authors:  Filip Björklund; Magnus Ekström
Journal:  Ann Am Thorac Soc       Date:  2022-10

8.  Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease.

Authors:  Magnus P Ekström; Claes Jogréus; Kerstin E Ström
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

9.  Chronic obstructive pulmonary disease (COPD) during the two last years of life--a retrospective study of decedents.

Authors:  Britt-Marie Sundblad; Sven-Arne Jansson; Lennarth Nyström; Peter Arvidsson; Bo Lundbäck; Kjell Larsson
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.